News and Media
News and Media
Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2019
Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform
October 14, 2019
Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy
September 18, 2019
Onxeo to Attend Key Investor and Scientific Conferences
September 11, 2019
Publication of the 2019 Half-Yearly Financial Report
July 31, 2019
Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update
July 25, 2019
The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation
July 1, 2019
Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase
June 20, 2019
Onxeo renews its equity financing line with Nice & Green as part of the financing of its business and strategic activities
June 7, 2019
Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors
May 28, 2019
Ordinary General Meeting of May 22, 2019
May 22, 2019
Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy
May 6, 2019
Publication of the 2018 Registration Document
April 8, 2019
Ordinary General Meeting on April 26, 2019
April 5, 2019
Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting
March 25, 2019
Press Release Signup
Subscribe to receive our Press Releases when they come out.
